ALK and non-small cell lung carcinoma: This includes Epidermal Growth Factor Receptor (EGFR) inhibitors for EGFR-mutated NSCLC and Anaplastic Lymphoma Kinase (ALK) inhibitors for ALK-rearranged NSCLC [4, 5].